Cargando…

Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine

INTRODUCTION: In order to provide baseline data on genetic testing as a key element of personalised medicine (PM), Canadian physicians were surveyed to determine roles, perceptions and experiences in this area. The survey measured attitudes, practice, observed benefits and impacts, and barriers to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonter, Katherine, Desjardins, Clarissa, Currier, Nathan, Pun, Jason, Ashbury, Fredrick D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191410/
https://www.ncbi.nlm.nih.gov/pubmed/22021765
http://dx.doi.org/10.1136/bmjopen-2011-000110
_version_ 1782213651362480128
author Bonter, Katherine
Desjardins, Clarissa
Currier, Nathan
Pun, Jason
Ashbury, Fredrick D
author_facet Bonter, Katherine
Desjardins, Clarissa
Currier, Nathan
Pun, Jason
Ashbury, Fredrick D
author_sort Bonter, Katherine
collection PubMed
description INTRODUCTION: In order to provide baseline data on genetic testing as a key element of personalised medicine (PM), Canadian physicians were surveyed to determine roles, perceptions and experiences in this area. The survey measured attitudes, practice, observed benefits and impacts, and barriers to adoption. METHODS: A self-administered survey was provided to Canadian oncologists, cardiologists and family physicians and responses were obtained online, by mail or by fax. The survey was designed to be exploratory. Data were compared across specialties and geography. RESULTS: The overall response rate was 8.3%. Of the respondents, 43%, 30% and 27% were family physicians, cardiologists and oncologists, respectively. A strong majority of respondents agreed that genetic testing and PM can have a positive impact on their practice; however, only 51% agreed that there is sufficient evidence to order such tests. A low percentage of respondents felt that they were sufficiently informed and confident practicing in this area, although many reported that genetic tests they have ordered have benefited their patients. Half of the respondents agreed that genetic tests that would be useful in their practice are not readily available. A lack of practice guidelines, limited provider knowledge and lack of evidence-based clinical information were cited as the main barriers to practice. Differences across provinces were observed for measures relating to access to testing and the state of practice. Differences across specialties were observed for the state of practice, reported benefits and access to testing. CONCLUSIONS: Canadian physicians recognise the benefits of genetic testing and PM; however, they lack the education, information and support needed to practice effectively in this area. Variability in practice and access to testing across specialties and across Canada was observed. These results support a need for national strategies and resources to facilitate physician knowledge, training and practice in PM.
format Online
Article
Text
id pubmed-3191410
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-31914102011-10-13 Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine Bonter, Katherine Desjardins, Clarissa Currier, Nathan Pun, Jason Ashbury, Fredrick D BMJ Open Genetics and Genomics INTRODUCTION: In order to provide baseline data on genetic testing as a key element of personalised medicine (PM), Canadian physicians were surveyed to determine roles, perceptions and experiences in this area. The survey measured attitudes, practice, observed benefits and impacts, and barriers to adoption. METHODS: A self-administered survey was provided to Canadian oncologists, cardiologists and family physicians and responses were obtained online, by mail or by fax. The survey was designed to be exploratory. Data were compared across specialties and geography. RESULTS: The overall response rate was 8.3%. Of the respondents, 43%, 30% and 27% were family physicians, cardiologists and oncologists, respectively. A strong majority of respondents agreed that genetic testing and PM can have a positive impact on their practice; however, only 51% agreed that there is sufficient evidence to order such tests. A low percentage of respondents felt that they were sufficiently informed and confident practicing in this area, although many reported that genetic tests they have ordered have benefited their patients. Half of the respondents agreed that genetic tests that would be useful in their practice are not readily available. A lack of practice guidelines, limited provider knowledge and lack of evidence-based clinical information were cited as the main barriers to practice. Differences across provinces were observed for measures relating to access to testing and the state of practice. Differences across specialties were observed for the state of practice, reported benefits and access to testing. CONCLUSIONS: Canadian physicians recognise the benefits of genetic testing and PM; however, they lack the education, information and support needed to practice effectively in this area. Variability in practice and access to testing across specialties and across Canada was observed. These results support a need for national strategies and resources to facilitate physician knowledge, training and practice in PM. BMJ Group 2011-07-29 /pmc/articles/PMC3191410/ /pubmed/22021765 http://dx.doi.org/10.1136/bmjopen-2011-000110 Text en © 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Genetics and Genomics
Bonter, Katherine
Desjardins, Clarissa
Currier, Nathan
Pun, Jason
Ashbury, Fredrick D
Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine
title Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine
title_full Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine
title_fullStr Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine
title_full_unstemmed Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine
title_short Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine
title_sort personalised medicine in canada: a survey of adoption and practice in oncology, cardiology and family medicine
topic Genetics and Genomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191410/
https://www.ncbi.nlm.nih.gov/pubmed/22021765
http://dx.doi.org/10.1136/bmjopen-2011-000110
work_keys_str_mv AT bonterkatherine personalisedmedicineincanadaasurveyofadoptionandpracticeinoncologycardiologyandfamilymedicine
AT desjardinsclarissa personalisedmedicineincanadaasurveyofadoptionandpracticeinoncologycardiologyandfamilymedicine
AT curriernathan personalisedmedicineincanadaasurveyofadoptionandpracticeinoncologycardiologyandfamilymedicine
AT punjason personalisedmedicineincanadaasurveyofadoptionandpracticeinoncologycardiologyandfamilymedicine
AT ashburyfredrickd personalisedmedicineincanadaasurveyofadoptionandpracticeinoncologycardiologyandfamilymedicine